NVAX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVAX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Novavax's share price is $3.95. Novavax's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.24. Hence, Novavax's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Novavax's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 13 years, Novavax's highest Price-to-Operating-Cash-Flow Ratio was 257.14. The lowest was 14.65. And the median was 23.32.
Novavax's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-1.43. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.24.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -112.40% per year.
During the past 13 years, Novavax's highest 3-Year average Operating Cash Flow per Share Growth Rate was 57.90% per year. The lowest was -112.40% per year. And the median was 0.40% per year.
The historical data trend for Novavax's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | 32.96 | - | - |
Novavax Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Novavax's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Novavax's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Novavax's Price-to-Operating-Cash-Flow falls into.
Novavax's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 3.95 | / | -7.24 | |
= |
Novavax's Share Price of today is $3.95.
Novavax's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.24.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Novavax's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Filip Dubovsky | officer: President, R&D | C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878 |
Gregory M Glenn | officer: President, R&D | 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878 |
Elaine O'hara | officer: EVP, Chief Strategy Officer | 333 NORTH WARREN AVENUE, MALVERN PA 19355 |
John C Jacobs | director, officer: President and CEO | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Richard J Rodgers | director | C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451 |
James F Young | director | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Herrmann John A Iii | officer: SVP, General Counsel | C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878 |
Stanley C Erck | director, officer: President and CEO | 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878 |
John Trizzino | officer: SVP, CBO and CFO | 9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850 |
David M Mott | director | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
James Patrick Kelly | officer: EVP, CFO and Treasurer | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Gary C Evans | director | 1048 TEXAN TRAIL, GRAPEVINE TX 76051 |
Rachel K. King | director | C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
Mcmanus Michael A Jr | director | 241-02 NORTHERN BLVD, DOUGLASTON NY 11362 |
Margaret G Mcglynn | director | C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
From GuruFocus
By PRNewswire • 11-14-2023
By PRNewswire • 10-31-2023
By PRNewswire PRNewswire • 06-15-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire • 08-01-2023
By GuruFocus Research • 11-09-2023
By PRNewswire • 10-18-2023
By PRNewswire • 09-07-2023
By PRNewswire PRNewswire • 05-12-2023
By PRNewswire PRNewswire • 05-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.